Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA approves first microencapsulated benzoyl peroxide for rosacea

By Brian Buntz | April 25, 2022

Epsolay-Galderma-Sol-Gel

Image courtesy of Sol-Gel/Galderma

Sol-Gel (Nasdaq:SLGL) and Galderma have announced that it has won FDA approval for Epsolay cream, a proprietary topical formulation of benzoyl peroxide, 5%, for treating inflammatory rosacea lesions.

Rosacea is a common condition, but experts have struggled to estimate its global prevalence. A 2018 estimate in the British Journal of Dermatology concluded that the condition affects between 5% and 46% of the adult population.

Galderma and Sol-Gel report that Epsolay Cream is the only topical treatment shown to relieve bumps and blemishes associated with rosacea.

Galderma, the world’s largest independent dermatology company, will commercialize the cream in the U.S.

First prepared in 1958, benzoyl peroxide is widely used as an over-the-counter topical acne treatment.

Epsolay cream is encapsulated within patented silica shells that steadily release benzoyl peroxide to optimize efficacy and tolerability. In particular, benzoyl peroxide can cause skin irritation in patients with sensitive skin.

Sol-Gel reports that 82% of rosacea patients feel their condition is uncontrolled.

In clinical studies, Epsolay decreased bumps and blemishes associated with rosacea by almost 70% in 12 weeks.

Sol-Gel reports that almost half of rosacea patients receiving the cream had clear or nearly clear skin after 12 weeks of receiving the cream treatment.


Filed Under: Dermatology
Tagged With: benzoyl peroxide, dermatology, Epsolay, Galderma, rosacea, Sol-Gen
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Takeda
TAK-279, an oral small-molecule TYK2 inhibitor offering the convenience of a once-daily pill and biologic-like clinical responses
AbbVie 770 logo
Upadacitinib shows promising results in ongoing phase 3 atopic dermatitis studies
plant under a microscope
Legacy Healthcare aims to upend alopecia areata treatment with a botanical drug
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE